Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24866488 | 0.99 | KDM4E (0.44) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL21399257 | 0.87 | KDM4E (0.45) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL23173482 | 0.78 | KDM4E (0.49) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL23172972 | 0.74 | KDM5A (0.36) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL24097086 | 0.72 | CDK4 (0.33) | KDM4ECYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL21388716 | 0.69 | KDM4E (0.43) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL21399059 | 0.69 | BCHE (0.49) | HPGDKDM4EPDE2AADORA1ADORA2A | |
| SCHEMBL6100817 | 0.67 | MEN1 (0.47) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL21380926 | 0.67 | HPGD (0.47) | HPGDKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL21398887 | 0.66 | KDM4E (0.44) | HPGDKDM4EMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | HPGD 2665/4885KDM4E 1596/4885MEN1 2793/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | HPGD 2665/4885KDM4E 1596/4885MEN1 2793/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | HPGD 2665/4885KDM4E 1596/4885MEN1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.